Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). by Lundin, J, Kimby, E, Björkholm, M, Broliden, P, Celsing, F, Hjalmar, V, Möllgård, L, Rebello, P, Hale, G, Waldmann, H, Mellstedt, H, Osterborg, A

Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL). by Lundin, J, Kimby, E, Bjorkholm, M, Celsing, F, Hale, G, Hjalmar, V, Merup, M, Petrescu, A, Tullgren, O, Waldmann, H, Mellstedt, H, Osterborg, A

Collaborative meta-analysis of randomised trials in chronic lymphocytic leukaemia (CLL) by Binet, J, Dighiero, G, Catovsky, D, Hansen, M, Jaksic, B, Kimby, E, Montserrat, E, Richards, S, Wiernik, P, Grp, C, Cll, F, Grp, D, Sweden, L

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. by Hale, G, Rebello, P, Brettman, L, Fegan, C, Kennedy, B, Kimby, E, Leach, M, Lundin, J, Mellstedt, H, Moreton, P, Rawstron, A, Waldmann, H, Osterborg, A, Hillmen, P

Chemotherapeutic options in chronic lymphocytic leukemia: A meta-analysis of the randomized trials by Geisler, C, Hansen, M, Yeap, B, Wiernik, P, Binet, J, Chastang, C, Dighiero, G, Travade, P, Jaksic, B, Brugiatelli, M, Kimby, E, Catovsky, D, Hamblin, T, Richards, S, Bosch, F, Fontanillas, M, Montserrat, E, Alison, R, Clarke, M, Duong, H, Elphinstone, P, Evans, V, Godwin, J, Gray, R, Greaves, E